ZIVO offered the underwriters a 45-day option to purchase an additional 414,000 common shares and/or 414,000 warrants at the public offering price to cover the excess offering as part of the offer. Maxim Group LLC partially exercised the excess distribution option by purchasing an additional 414,000 warrants at a price of $ 0.01 per warrant, resulting in $ 4,140 in additional gross revenue.
A biotechnology and agricultural technology research and development business called Zivo Bioscience (ZIVO). Today, the company announced the closure of a previously announced underwriter public offering of 2,760,000 units at a price to the public of $ 5.00 per unit.
Zivo Bioscience (ZIVO) is a Michigan – based biotechnological/agro technical company dedicated to the research of the health and nutritional benefits of bioactive compounds derived from its proprietary algae crops, as well as the development of natural bioactive compounds for use as food additives and food ingredients. As a result, investors should exercise greater caution when taking into consideration this firm as an investment option.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.